Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, local tolerability and pharmacokinetic
parameters of TOL-463 intravaginal dosage forms in both healthy, nonpregnant females
following single dose administration (Part 1), and in nonpregnant women with vaginitis
following multi-dose administration (Part 2).
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)